跳至主要内容
临床试验/NCT07388615
NCT07388615招募中2 期

The Effect of Echinacea (Immulant ®) in the Treatment of CRYPTOSPORIDIOSIS in Immunocompromised Children

Al-Azhar University1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2026年1月18日最近更新:
干预措施

试验速览

阶段
2 期
状态
招募中
入组人数
60
试验地点
1
主要终点
To measure the changes in parasite count in stool samples after treatment

研究概览

简要总结

This study aims to:

  1. To evaluate the effectiveness of Immulant ® addition to standard treatment in reducing clinical symptoms of Cryptosporidiosis in immunocompromised children.
  2. To measure the changes in parasite count in stool samples after treatment with Immulant ®.
  3. To assess the safety and tolerability of Immulant ® in children participating in the study.

详细描述

The present prospective study will be (open labelled) Randomized Clinical Trial and was approved by the Research Ethical Committee Of national nutritional institute. Oral and written consent will be obtained from all patients and controls after a full explanation of the study.

A total of at least 60 immunocompromised children consecutively diagnosed with cryptosporidiosis were recruited from the outpatient clinic of National Nutritional Institute.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
5 Years 至 12 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Clinical diagnosis of Cryptosporidiosis Disease
  • Age from 5-12 years
  • Immunocompromised children
  • Not receiving any drugs causing immunosuppression

排除标准

  • Patients undergoing organ transplantation
  • Patients suffering from autoimmune diseases.
  • Patients suffering from hypersensitivity of this plant extract

研究组 & 干预措施

interventional arm

Active Comparator

干预措施: Echinacea Extract (Drug)

结局指标

主要结局

To measure the changes in parasite count in stool samples after treatment

时间窗: six months

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Maha Abd Elrhman

Principal Investigator

Al-Azhar University

研究点 (1)

Loading locations...

相似试验